CAMEO+ eventCORPORATE2026-05-06馃嚭馃嚫
Arrowhead and Madrigal sign global license for MASH RNAi therapy
source: Arrowhead Pharmaceuticals -> target: Madrigal Pharmaceuticals
On 2026-05-06, Arrowhead Pharmaceuticals signed an exclusive global license agreement with Madrigal Pharmaceuticals for Arrowhead鈥檚 investigational RNAi therapy ARO-PNPLA3 for MASH. The deal gives Madrigal global rights to develop, manufacture, and commercialize the asset, with a $25 million upfront payment and up to $975 million in milestones plus royalties.
0.16Significance2.0Magnitude0.1Systemic0.3Market1Articles
Location
PasadenaCaliforniaNorth AmericaUnited StatesNorth America34.148, -118.144
Story Links